Regarding prophylaxis of transfusion-associated CMV and parvovirus B19 infections, see section 11.4. Symptoms: Occurrence of specific symptoms of the infection in question after expiration of the respective incubation time (characteristic time interval between transfusion and onset of disease!). Diagnosis: Determination of specific antibodies, proof of virus genome, if necessary, comparison of viral genome sequences in Rabbit Polyclonal to Granzyme B recipient and donor. 35]) and the frequency of clinical reactions to contaminated preparations (approximately 1:100,000 [12, 14, 15]), since a large proportion of contaminated transfused platelet concentrates did not lead to clinical reactions Lyn-IN-1 [35]. Specific infections with or by blood transfusion are extremely rare [4, 8]. Symptoms: Depending on the degree of severity, the symptoms of a septic reaction may resemble those of an immediate-type hemolytic transfusion reaction or those of a febrile nonhemolytic transfusion reaction (grade II to grade III). Most frequent are fever, chills, emesis and/or diarrhea, pronounced hypotension and tachycardia, which may often occur during transfusion, rarely several hours later. Diagnosis: It is most essential to rule out an immediate-type hemolytic transfusion reaction. In all grade II and grade III reactions, the microbiological laboratory should first carry out a smear from the blood product using Gram’s staining. In addition, upon suspicion of bacterial contamination microbiological cultures from the transfused units and from the recipient’s blood should be performed at suitable temperatures. If the same species of bacteria is detected in the blood component and in the patient sample, a comparison of genome sequences of bacteria should be performed. Differential diagnoses: Acute hemolysis, allergic reaction, febrile nonhemolytic transfusion reaction. Therapeutic measures: Discontinue transfusion, maintain venous access. Symptomatic therapy, if necessary shock treatment, targeted antibiotic therapy. Prophylaxis: Visual control of all blood products immediately prior to transfusion regarding intactness of the blood bag. Bacterial contamination can occasionally become recognized by clot and lump formation, discoloration or lack of the swirling Lyn-IN-1 effect in platelet concentrates (cloudy opalescence on inspection against the light). Control of the expiration day prior to transfusion. Verification of the chilly chain in the case of RBC concentrates. On principle, blood components must by no means be opened except for introducing Lyn-IN-1 the transfusion arranged immediately prior to transfusion. Transfusion of blood parts within 6 h after opening [1]. 11.2.5 Transfusion-Related Acute Lung Injury Etiology and frequency: TRALI is caused by antibodies to patients’ leukocytes in donor plasma (rarely in recipients’ plasma). The triggered leukocytes obstruct the pulmonary microcirculation and cause pulmonary edema. Up to 25% of afflicted individuals pass away [14, 24]. In rare cases, TRALI can also have a non-immuno-genic etiology, but in these instances medical symptoms are mostly insignificant. Symptoms: During or up to 6 h after transfusion, rapidly increasing dyspnea evolves together with hypoxemia (SpO2 90% on ambient air flow or FiO2 300) and bilateral pulmonary infiltrates become apparent in chest X-ray. Sometimes hypotension and fever are observed. 70% of individuals require aided respiration. Analysis: In all of the individuals developing a unique acute dyspnea in the context of transfusion the O2 saturation (minimum) shall be determined by pulse oxymetry and a chest X-ray shall be made, at least in the posterior-anterior look at. In individuals with TRALI the O2 saturation is definitely below 90% and the X-ray displays newly emerged bilateral infiltrates. Concerning differential analysis (table 11.1.2). If TRALI is definitely suspected clinically, the pharmaceutical manufacturer of the blood component must be educated. In cooperation with the going to physician, the manufacturer must identify the product(s) probably triggering the symptoms. Sera from your donors involved must be investigated for the presence of leukocyte-reactive antibodies, in particular antibodies to HLA class I and class II, as well as to granulocyte-specific antigens (HNA). When antibodies are recognized in the donor, an recognition of the antibodies and a typing of the recipient’s antigens should be targeted for. As a rule, it.
